SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001193125-23-205011
Filing Date
2023-08-07
Accepted
2023-08-07 16:25:35
Documents
8

Document Format Files

Seq Description Document Type Size
1 S-3 d541146ds3.htm S-3 456767
2 EX-5.1 d541146dex51.htm EX-5.1 5548
3 EX-23.1 d541146dex231.htm EX-23.1 1690
4 EX-FILING FEES d541146dexfilingfees.htm EX-FILING FEES 30137
5 GRAPHIC g541146g0806211048287.jpg GRAPHIC 2141
6 GRAPHIC g541146g13n03.jpg GRAPHIC 595199
7 GRAPHIC g541146g13n10.jpg GRAPHIC 680365
8 GRAPHIC g541146g45k65.jpg GRAPHIC 2936
  Complete submission text file 0001193125-23-205011.txt   2242641
Mailing Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453 6176515940
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-273769 | Film No.: 231147951
SIC: 2834 Pharmaceutical Preparations